Fisher Asset Management LLC Decreases Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Fisher Asset Management LLC reduced its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 88.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,198 shares of the life sciences company’s stock after selling 352,525 shares during the period. Fisher Asset Management LLC’s holdings in Integra LifeSciences were worth $1,070,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. KBC Group NV boosted its position in Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after buying an additional 1,120 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after buying an additional 2,800 shares during the last quarter. Empowered Funds LLC purchased a new position in Integra LifeSciences in the 4th quarter valued at about $180,000. Romano Brothers AND Company purchased a new position in Integra LifeSciences in the 4th quarter valued at about $204,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. purchased a new position in Integra LifeSciences in the 4th quarter valued at about $204,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley initiated coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $21.87 on Thursday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $36.99. The company’s 50-day simple moving average is $23.79 and its 200-day simple moving average is $21.88. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -242.97, a PEG ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter last year, the company posted $0.89 earnings per share. Integra LifeSciences’s revenue was up 11.5% on a year-over-year basis. Equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.